Date:9/24/2010

oncept that calcitonin may have a role in reducing cartilage degradation and bone loss as part of a combination therapy for treating osteoarthritis.  In addition, in our studies the synergistic effects were achieved using low doses of the compounds.  This type of combination therapy may have the potential to treat osteoarthritis more effectively while reducing the safety concerns associated with higher doses of existing anti-arthritis agents."

The annual OARSI Congress is a global forum for all people interested and involved in osteoarthritis research and treatment: basic scientists from academia and industry, clinical investigators, physicians (radiologists, rheumatologists, orthopaedic surgeons, etc.), allied health professionals and policy makers.  It is being held in Brussels, Belgium September 23-26, 2010.  For more information, visit www.oarsi.org/meetings/10Congress/index.php.

About Tarsa TherapeuticsTarsa Therapeutics is developing an oral formulation of calcitonin for the treatment of osteoporosis.  Calcitonin is a peptide hormone that inhibits bone resorption, the underlying process that can result in osteoporosis.  Availability of an oral formulation is expected to generate wider use of this established osteoporosis treatment, which currently is available only in injectable and intranasal formulations.  Tarsa's oral calcitonin has generated promising data in Phase II studies, and the ORACAL study, a global Phase III clinical trial, has completed patient enrollment.  Tarsa is based in Philadelphia, PA.  For more information, visit www.tarsatherapeutics.com.

About Unigene Laboratories, Inc.  Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics.  The Company is building a robust portfolio of proprie
'/>"/>

SOURCE Tarsa Therapeutics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute